Showing 2681-2690 of 5258 results for "".
- iRestore Expands Reseller Programhttps://practicaldermatology.com/news/irestore-expands-reseller-program/2457677/The iRestore Laser Hair Growth System from Freedom Laser Therapy is now more widely available, thanks to an expanded reseller program for the drug-free, pain-free laser hair restoration device. The reseller program now offers an affiliate model that enables sales representative
- Game On: Head-to-head Trials to Enhance Competition in PsO Markethttps://practicaldermatology.com/news/head-to-head-trials-to-enhance-competition-in-pso-market/2457684/An increase in head-to-head trials will enhance the competition within the psoriasis market, according to
- Colorescience Receives Patent for Even Up Clinical Pigment Corrector Formulationhttps://practicaldermatology.com/news/colorescience-receives-patent-for-even-up-clinical-pigment-corrector-formulation/2457687/The US Patent and Trademark Office (USPTO) has granted a patent for Colorescience’s LUMIRA™ formulation, a clinically tested, highly effective complex that addresses the appearance of skin discoloration, found in the 3-in-1 treatment product, Even Up® Clinical Pigment P
- Novartis Enters Licensing Deal for IL-17C Compound for Atopic Dermatitishttps://practicaldermatology.com/news/novartis-enters-licensing-deal-for-il-17c-compound-for-atopic-dermatitis/2457689/Novartis has entered into an exclusive license agreement with biotech companies Galapagos NV, Mechelen (Belgium) and MorphoSys AG, Planegg/Munich (Germany) to acquire the exclusive global development and marketing rights to MOR106 for atopic dermatitis and all other potential indications. Novarti
- Life Sciences Industry Eyes $1.5 Trillion Milestonehttps://practicaldermatology.com/news/life-sciences-industry-eyes-15-trillion-milestone/2457703/The life sciences industry is nearing a $1.5 trillion milestone, according to an analysis from Frost & Sullivan. The firm’s Global Life Sciences Industry Outlook, 2018 report finds that healthcare digitization and consumerization, the explosion of patient data, and the emergence of
- Rare Pediatric Skin Conditions Often Get Expensive, Inconsistent Carehttps://practicaldermatology.com/news/rare-pediatric-skin-conditions-often-get-expensive-inconsistent-care/2457704/Children with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have high rates of complications — resulting in long and costly hospital stays — and that treatment strategies varied among health care providers, according to the first large-scale analysis, which is
- XELJANZ Receives EU Marketing Authorization for Adults with Active PsAhttps://practicaldermatology.com/news/xeljanz-receives-eu-marketing-authorization-for-adults-with-active-psa/2457706/The European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-mod
- First EB Patient Enrolled in PK Study of Diacerein 1% Ointmenthttps://practicaldermatology.com/news/first-eb-patient-enrolled-in-pk-study-of-diacerein-1-ointment/2457716/The first patient has been enrolled in a new Phase 1 study evaluating the pharmacokinetics (PK) and safety of Castle Creek Pharmaceuticals’ diacerein 1% ointment (CCP-020) under maximum use conditions in patients with epidermolysis bullosa (EB)
- Michael Mazen Jafar is New Chief Marketing Officer at Evolushttps://practicaldermatology.com/news/michael-mazen-jafar-is-new-chief-marketing-officer-at-elovus/2457722/Evolus, Inc. has expanded its management team with the appointment of Michael Mazen Jafar as Chief Marketing Officer. Mr. Jafar joins Evolus from Allergan where he most recently served as Vice President, Medical Aesthetics. At Allergan Mr. Jafar led the commercial launch of Juve
- eRelevance Launches Suite of Services to Support Lead Conversionhttps://practicaldermatology.com/news/erelevance-launches-suite-of-services-to-support-lead-conversion/2457726/eRelevance Corporation has launched a suite of tech-powered services to help